This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peltola, H.
Right arrow Articles by Saxén, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peltola, H.
Right arrow Articles by Saxén, H.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 101 No. 4 April 1998, pp. 658-662

Single-dose and Steady-state Pharmacokinetics of a New Oral Suspension of Ciprofloxacin in Children

Received Mar 25, 1997; accepted Aug 20, 1997.

Heikki Peltola*, Pentti Ukkonen*, Harri Saxén*, and Heino Stabeta Dagger

From the * Helsinki University Central Hospital, Hospital for Children and Adolescents, Helsinki, Finland; and Dagger  Bayer AG, Pharma Research Center, Wuppertal, Germany.

Objective.  Quinolones are used ever increasingly in pediatrics, although officially they are still contraindicated. Lack of evidence of arthropathic effects in human offspring favors their use, but little is known about the pharmacokinetics of oral or parenteral ciprofloxacin in children, especially those without cystic fibrosis.

Design.  We studied 16 non-cystic fibrosis patients ranging in age from 0.3 to 7.1 years to whom the new suspension formulation of ciprofloxacin (10 mg/kg body weight) was given orally three times daily. Single-dose and steady-state pharmacokinetic parameters were elucidated.

Results.  Ciprofloxacin was rapidly absorbed. The maximum plasma concentrations, with the means varying from 1.7 to 3.6 mg/L, were reached within 1 hour, almost regardless of whether single-dose administration or steady state. The mean oral clearance was lower in children <6 years of age than in those >= 6 years. Terminal half-life values, with the means varying only between 4.2 and 5.1, suggest that dosing recommendations based on body weight are pertinent, although caution should be exercised in small infants. No arthropathic or other adverse events attributable to ciprofloxacin suspension were observed.

Conclusion.  A dose of the suspension form of ciprofloxacin of 10 mg/kg body weight given orally three times daily seems appropriate in children, provided the drug is clearly indicated.

Key words: ciprofloxacin, quinolones, pediatrics, children, oral ciprofloxacin, suspension, mixture.




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
P. Rajagopalan and M. R. Gastonguay
Population Pharmacokinetics of Ciprofloxacin in Pediatric Patients
J. Clin. Pharmacol., July 1, 2003; 43(7): 698 - 710.
[Abstract] [Full Text] [PDF]